STOCK MARKET BSE NSE

Bharat Biotech to present evidence of vaccine efficacy by February-March

According to Ella, the company plans to produce the doses in four of its facilities based in Hyderabad and Bengaluru. 

Published: 05th January 2021 08:54 AM  |   Last Updated: 05th January 2021 08:54 AM   |  A+A-

'COVAXIN' was developed and manufactured at the company's Bio-safety Level-III high containment facility at Genome Valley.

'COVAXIN' was developed and manufactured at the company's Bio-safety Level-III high containment facility at Genome Valley.  (Photo| Special Arrangement)

By Express News Service

NEW DELHI: Under fire for receiving approval for its Covid-19 vaccine Covaxin in the country without presenting any efficacy data, Bharat Biotech on Monday confirmed that it has not presented any results from the late-stage trials and added that evidence of its efficacy will be available by February-March.

Company chairman Krishna Ella, in a virtual press briefing, said that  his company “gave excellent safety data tested on around 25,000 participants”, adding that they are “confident of having efficacy above the set benchmark of 50 %”.

ALSO READ: Covaxin being targeted because it's made by Indian company, says Bharat Biotech MD

Covaxin, along with Covishield by SII, had been granted restricted use permission in the country last week and is expected to be launched in days ahead. According to Ella, the company plans to produce the doses in four of its facilities based in Hyderabad and Bengaluru. 

“We have 20 million doses right now. We can manufacture 700 million doses in 2021,” Ella said adding that the company has manufactured a stock pile of one crore doses already even before the vaccine was cleared by the drug regulator. 

He also said that while the talks are on with the government on pricing and purchase agreements, the cost will be higher in the beginning but may come down later depending on the market conditions. 

Ella said that his company is ready to roll out the vaccine, whose 50 lakh doses have been sent to the central drugs laboratory at Kasauli for testing, any day if the government allows it. “I would love to roll out tomorrow.” 

The company said that it is confident about the high efficacy rate of its vaccine, given the tested nature of the platform(inactivated virus) it uses and robust immune response it showed in pre-clinical trials and early stage human trials. ens



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp